4-[[(E,4E)-4-(3,4-dihydro-2H-naphthalen-1-ylidene)-3-methylbut-2-enoyl]amino]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[[(E,4E)-4-(3,4-dihydro-2H-naphthalen-1-ylidene)-3-methylbut-2-enoyl]amino]benzoic acid
• 化学式: C₂₂H₂₁NO₃
• 分子量: 347.4
• InChiKey: DNFCBYFRHBUMCC-FHFAONFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• LATENT HUMAN IMMUNODEFICIENCY VIRUS REACTIVATION
  申请人：THE UAB RESEARCH FOUNDATION

  公开号：US20140295012A1

  公开（公告）日：2014-10-02

  Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-fB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-fB activity without a second delayed increase in NF-fB activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). The HRF can, for example, comprise a Massilia flagellin polypeptide or fragment thereof. Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.
• METHODS OF REACTIVATING A LATENT HUMAN IMMUNODEFICIENCY VIRUS
  申请人：THE UAB RESEARCH FOUNDATION

  公开号：US20150216926A1

  公开（公告）日：2015-08-06

  Provided herein are methods of reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell or subject. The methods include contacting the cell with or administering to the subject one or more proteasome inhibitors, and contacting the cell with or administering to the subject one or more reactivating agents. Also provided are methods of treating an HIV infection in a subject. The methods include administering to the subject one or more proteasome inhibitors, administering to the subject one or more reactivating agents and administering to the subject one or more anti-retroviral agents.